Displaying 1421 - 1440 of 4794
Canon Inc. and Toshiba Corporation
Canon Inc. and Toshiba Corporation have agreed to settle Federal Trade Commission charges that the companies violated the premerger notification and waiting period requirements of the Hart-Scott-Rodino Act, or HSR Act, when Canon acquired Toshiba Medical Systems Corporation from Toshiba in 2016.
Canon Inc., Toshiba Corporation Agree to Pay $5 Million for Violating Federal Antitrust Laws
FTC Hearings on Competition and Consumer Protection in the 21st Century Conclude with a Session Featuring State Attorneys General
1906010 Informal Interpretation
Pharmaceutical Agreement Filing Procedures Updated
FTC Submits Comment on Proposed Information Blocking Rule to the Department of Health & Human Services Office of the National Coordinator for Health Information Technology (ONC)
1906004 Informal Interpretation
1905004 Informal Interpretation
FTC Announces Agenda for the 14th and Final Session of Hearings on Competition and Consumer Protection in the 21st Century
1905003 Informal Interpretation
FTC Staff Comment Before the Department of Health and Human Services Regarding the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program
FTC Approves Final Order Imposing Conditions on Merger of Titanium Dioxide Companies Tronox Limited and Cristal
Tronox/Cristal USA, In the Matter of
The FTC issued an administrative complaint (and authorized staff to seek a TRO and PI which have not been filed) challenging the merger of two top suppliers of chloride process titanium dioxide (TiO2), a white pigment used in a wide variety of products including paint, industrial coatings, plastic, and paper. The FTC’s administrative complaint charges that Tronox Limited’s proposed acquisition of competitor Cristal, for $1.67 billion and a 24 percent stake in the combined entity, would violate the antitrust laws by significantly reducing competition in the North American market (comprised of the United States and Canada) for chloride process titanium dioxide. The FTC alleges that the acquisition, if consummated, would increase the risk of coordinated action among the remaining competitors, and increase the risk of future anticompetitive output reductions by Tronox.
1905001 Informal Interpretation
FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Displaying 1421 - 1440 of 4794